New Study Links Pediatric GLP-1 Medications to Nutritional Deficiencies
Children and adolescents prescribed GLP-1 medications for weight loss, type 2 diabetes, or prediabetes face a notable risk of developing nutritional deficiencies. According to a study published in the academic journal Childhood Obesity, nearly one in six pediatric patients—specifically 16.8%—received a nutritional deficiency diagnosis within their first year of starting GLP-1 treatment.
The research, led by specialists at the Ann & Robert H. Lurie Children’s Hospital of Chicago, highlights vitamin D as the most frequently identified shortfall. Investigators found that 12.4% of the young patients developed a vitamin D deficiency within the first twelve months of initiating the medication regimen.
Senior author Justin Ryder, PhD, serves as the Vice Chair of Research for the Department of Surgery at Lurie Children’s Hospital and is an Associate Professor of Surgery and Pediatrics at the Northwestern University Feinberg School of Medicine. Commenting on the findings, Dr. Ryder emphasized the unique vulnerability of youth undergoing treatment during critical life stages. As the pediatric use of GLP-1 therapies expands, understanding the associated health risks during periods of rapid growth and pubertal development becomes vital.
Dr. Ryder noted that essential nutrients like iron, calcium, and vitamin D demand particular vigilance during adolescence. Shortages in these key components during developmental years can carry lasting consequences for overall bodily maturation and skeletal health, making proactive clinical monitoring essential.
Despite the documented risks, the investigation uncovered a significant gap in preventative nutritional support following the initiation of therapy. The data revealed that only 5% of the young patients received professional nutritional counseling within the first 30 days of beginning a GLP-1 prescription. Furthermore, fewer than 25% obtained nutritional counseling within a six-month window.
To conduct the evaluation, Dr. Ryder and fellow researchers analyzed national administrative claims data spanning from 2017 to 2022. This comprehensive dataset covered more than 100 million patients and allowed the team to isolate a cohort of 2,031 GLP-1 users aged 10 to 17 years. To ensure accuracy, the selected participants met strict continuous enrollment criteria and possessed no prior medical history of nutritional deficiencies.
Within this specific demographic cohort, the analysis showed that liraglutide was the most commonly prescribed GLP-1 medication, accounting for 78.6% of the cases. Dulaglutide followed at 10.4%, while semaglutide represented 9.1% of the total prescriptions issued.
The study authors advocate for a shift in clinical strategy, emphasizing the necessity of integrating proactive nutritional management into treatment plans right from the start. Rather than waiting to address shortfalls only after a formal deficiency diagnosis has been made, healthcare providers can better safeguard pediatric patients by anticipating these nutritional challenges.
By acknowledging the documented risks associated with these drugs, medical professionals are positioned to prevent avoidable harm in children undergoing therapy during such a pivotal chapter of their lives. The researchers hope these insights will encourage broader adoption of early dietary guidance in pediatric endocrinology and weight management clinics.
Source: News-Medical.net
